Diabetic Nephropathy Market Research Report Information by Diagnosis (Blood test, Urine tests, Imaging test, Renal function testing, kidney biopsy), Treatment (Medication, {Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptors Blockers, Antioxidant Inflammation Modulator, Calcium Channel Blockers, Diuretics, Others}, Kidney Dialysis, Transplant), Indication (Type-1 Diabetes, Type-2 Diabetes), End User (Hospital & Clinics, Surgical Centers, Others), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World)

Global Diabetic Nephropathy Market Overview

Diabetic Nephropathy Market Size was valued at USD 2.12 billion in 2022. The Diabetic Nephropathy Market industry is projected to grow from USD 2.25 billion in 2023 to USD 3.43 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.20% during the forecast period (2023 - 2030). The rising prevalence of diabetic patients and the increasing number of diabetic cases are the key market drivers boosting the growth of the diabetic nephropathy market.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Diabetic Nephropathy Market Trends

• Rising Prevalence of Diabetic Patients to Boost the Market Growth

There are numerous symptoms of diabetic nephropathy, but the most common is diabetes mellitus. End-stage renal failure is 10 times more common in people with diabetes mellitus. For instance, International Diabetes Federation 2022 estimates that diabetes was a cause of 6.7 million fatalities in 2021. Along with that, 1 in 10 individuals (20 to 79 years old) have diabetes, which affects 537 million people. By 2030, it is expected to reach 643 million, and by 2045, it will reach 783 million. Similarly, according to the International Diabetes Federation (IDF), 40% of diabetics may experience kidney failure in its ultimate stages. Furthermore, about 80% of end-stage renal failure is caused by diabetes and hypertension, either together or individually.

The introduction of new medicine for diabetic nephropathy in developing nations and the drug approvals by the FDA is offering a remunerative opportunity to the market. Due to an increase in both temporary and permanent chronic heart disease, hypertensive heart attacks, and diabetic nephropathy, angiotensin-converting enzyme inhibitors are frequently utilized. Thus, it stimulates market expansion.

Diabetic Nephropathy Market Segment Insights

Diabetic Nephropathy Diagnosis Insights

The diabetic nephropathy market segmentation, based on diagnosis, includes blood test, urine tests, imaging test, renal function testing, and kidney biopsy. The blood test segment held the majority share in 2022 in respect to the diabetic nephropathy market revenue. This is primarily owing to the rising prevalence of patients suffering from diabetes. Therefore, increasing chronic diseases such as obesity, and diabetes, have increased the demand for blood tests.

July 2021:FDA approved Bayer AG's (Germany) Kerendia (finerenone) tablets to reduce the risk of decreasing kidney function, kidney failure, non-fatal heart attacks, cardiovascular death, and hospitalization due to heart failure in adults with chronic kidney disease associated with type 2 diabetes

Diabetic Nephropathy Treatment Insights

The diabetic nephropathy market segmentation, based on treatment, includes medication, kidney dialysis, and transplant. The medication segment dominated the market in 2022 in respect to the diabetic nephropathy market. This is attributed to the increasing number of chronic diseases such as obesity, diabetes, and other chronic illness that have increased the demand for medications.

April 2021:ClinicalTrials.gov, Boehringer Ingelheim (Germany) registered for a phase 2 clinical trial to study the efficacy of BI 685509 against diabetic nephropathy. The aim is to study the efficacy of the medicine for kidney function improvement

Diabetic Nephropathy Indication Insights

The diabetic nephropathy market segmentation, based on indication includes type-1 diabetes and type-2 diabetes. Type-2 diabetes held the largest market share in 2022 with respect to the diabetic nephropathy market revenue. This is attributed to the high prevalence of Diabetic Nephropathy (DN) cases in adults aged 20 and older with type 2 diabetes worldwide. More than 90% of diabetes diagnoses are type 2, and the number of persons with type 2 diabetes is increasing, though more quickly in low- and middle-income nations than in high-income nations. Thus, the rising incidence of diabetes type-2 patients may result in diabetic nephropathy which consequently promotes the neuropathic pain market.

May 2021:Novartis (Switzerland) signed a collaboration agreement and option to acquire Cellerys, a Zurich-based startup researching therapy to fight multiple sclerosis

Diabetic Nephropathy End User Insights

The diabetic nephropathy market segmentation, based on end user includes hospital & clinics, surgical centers, and others. The hospital & clinics held the largest market share in 2022 with respect to the diabetic nephropathy market revenue. Hospital & clinics have the highest market share as chronic kidney disease has become common across the globe and people suffering from chronic kidney disease have an increased risk of health complications. Based on one of the research articles from PLOS Medicine, adults suffering from chronic kidney disease have a higher hospitalization rate than the general population getting hospitalized. This eventually increases the use of drugs for treatment from hospital & clinics.

January 2021:Pharma Foods International Co. Ltd. (Japan) entered into an exclusive licensing agreement with Mitsubishi Tanabe Pharma Corporation (Japan) to develop a candidate antibody to treat autoimmune diseases

September 2019:Janssen Pharmaceuticals, Inc. (Belgium) announced the approval for Invokana (canagliflozin) by the US Food and Drug Administration (FDA) for reducing the progression of diabetic nephropathy heart failure chances in patients with type 2 diabetes and diabetic kidney disease

Figure 2: Diabetic Nephropathy Market, by End User, 2022 & 2030 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Diabetic Nephropathy Regional Insights

By region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. North America diabetic nephropathy held the largest market share in 2022. This is attributed to the increase in the prevalence of diabetic nephropathy, health care infrastructure, and increased use of combination drugs, as well as an increase in diabetic patients’ awareness of diabetic nephropathy.

Further, the major countries studied are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: DIABETIC NEPHROPATHY MARKET SHARE (%) BY REGION 2022

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe diabetic nephropathy market accounts for the second-largest market share due to the rising government and pharmaceutical organization efforts to raise awareness of kidney disease as well as the existence of generic manufacturers are also boosting the market growth. Further, the Germany diabetic nephropathy market held the largest market share, and the UK diabetic nephropathy market was the fastest-growing market in the European region.

The Asia-Pacific Diabetic Nephropathy market is expected to grow at a significant growth rate during the forecast period. This is due to the increased healthcare spending, increased market awareness of new diabetic drugs, and increase in the number of hospitals are factors expected to boost the market over the forecast period. Moreover, China diabetic nephropathy market held the largest market share, and the India diabetic nephropathy market was the fastest-growing market in the Asia-Pacific region. Hence, Asia-Pacific is anticipated to register the highest growth rate over the forecast period from 2023–2030.

Diabetic Nephropathy Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the diabetic nephropathy market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the diabetic nephropathy industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the diabetic nephropathy industry to benefit clients and expand the diabetic nephropathy market sector is to manufacture locally to reduce operating costs.

AstraZeneca (UK) is a leading biopharmaceutical company. It focuses on developing and commercializing prescribed medicines. It has three main therapy areas, namely, cardiovascular, and metabolic disease (CVMD), oncology, and respiratory. It is also active in areas such as neuroscience autoimmunity and infection. Their product portfolio includes medications in the field of oncology, cardiovascular, renal & metabolism, and respiratory diseases, among others. For instance, in 2021, AstraZeneca’s Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalization for heart failure (hHF) in adults with chronic kidney disease (CKD) at risk of progression.

Key Companies in the Diabetic Nephropathy Market Includes

• 
  

  Novartis AG (Switzerland)

  
  


• 
  

  Merck & Co., Inc. (US)

  
  


• 
  

  Abbott Laboratories (US)

  
  


• 
  

  Sanofi (France)

  
  


• 
  

  Eli Lilly and Company (US)

  
  


• 
  

  Reata Pharmaceuticals, Inc. (US)

  
  


• 
  

  Bayer AG (Germany)

  
  


• 
  

  AbbVie, Inc. (US)

  
  


• 
  

  AstraZeneca (UK)

  
  


• 
  

  Mitsubishi Tanabe Pharma Corporation (Japan)

  
  

Diabetic Nephropathy Industry Developments

January 2023:Boehringer Ingelheim (Germany) and Eli Lilly and Company (US) announced that US Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) investigating a potential new indication to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes. These tablets have been investigated as a possible therapy to reduce the chance of cardiovascular death and kidney disease progression in adults with chronic kidney disease.

August 2022:Bayer (Germany) launched Finerenone under the brand name Kerendia in India. Finerenone is a first-in-class non-steroidal, selective mineralocorticoid receptor antagonist indicated for patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D)

April 2021:AstraZeneca (UK) Farxiga has been approved in the US to treat chronic kidney disease in patients at risk of progression with and without type-2 diabetes

Diabetic Nephropathy Market Segmentation

Diabetic Nephropathy Diagnosis Outlook

• 
  

   Blood Test

  
  


• 
  

  Urine Test

  
  


• 
  

  Imaging Test

  
  


• 
  

  Renal Function Testing

  
  


• 
  

  Kidney Biopsy

  
  

 Diabetic Nephropathy Treatment Outlook

• 
  

   Medication

  
  
  
  
  • 
    

    Angiotensin-Converting Enzyme (ACE) Inhibitors

    
    
  
  
  • 
    

    Angiotensin II Receptors Blockers

    
    
  
  
  • 
    

    Antioxidant Inflammation Modulator

    
    
  
  
  • 
    

    Calcium Channel Blockers

    
    
  
  
  • 
    

    Diuretics

    
    
  
  
  • 
    

    Others

    
    
  
  
  
  


• 
  

   Kidney Dialysis

  
  


• 
  

  Transplant

  
  

 Diabetic Nephropathy Indication Outlook

• 
  

   Type-1 Diabetes

  
  


• 
  

  Type-2 Diabetes

  
  

Diabetic Nephropathy End User Outlook

• 
  

  Hospital & Clinics

  
  


• 
  

  Surgical Centers

  
  


• 
  

  Others

  
  

Diabetic Nephropathy Regional Outlook

• 
  

  North America

  
  

• 
  

  US

  
  


• 
  

  Canada

  
  

• 
  

  Europe

  
  

• 
  

  Germany

  
  


• 
  

  France

  
  


• 
  

  UK

  
  


• 
  

  Italy

  
  


• 
  

  Spain

  
  


• 
  

  Rest of Europe

  
  

• 
  

  Asia-Pacific

  
  
  
  
  • 
    

    China

    
    
  
  
  • 
    

    Japan

    
    
  
  
  • 
    

    India

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    South Korea

    
    
  
  
  • 
    

    Rest of Asia-Pacific

    
    
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America